| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94e448d4ce69c414a98df1dfdf1a3254
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_72736379a3a4af78fd9056a6c0ba6c9f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0368a4dd306afddc8557fce8a1e7d10b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec278f55741bfdd6fb9ab250e90b8085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_616e6deed59bf8c2b4a22363ae69e6e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_51761a0d748fa987e2d4ecea061efa21 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7155 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate |
1998-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ba38ae07afb657f11a59a23fdb1ea55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb8949d4ebe4ed09050ebfcea0c8fe8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ba65b67919801dc1671d96540a185af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87f247618bc3bf1d4a98ebedf1fb1593
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_620fe4e58efde4706d5a2ad94f49eb07 |
| publicationDate |
1998-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9848011-A1 |
| titleOfInvention |
Novel chimeric molecules |
| abstract |
The present invention relates generally to chimeric molecules and more particularly to interspecies cytokine receptor α-chain chimeras. Even more particularly, the present invention provides interspecies leukaemia inhibitory factor (LIF) receptor α-chain chimeras. The chimeric molecules of the present invention are useful inter alia as antagonists of human cytokine activities in vivo. In one embodiment, the present invention provides a polypeptide or a derivative or chemical equivalent thereof comprising first and second portions linked, bound or otherwise associated together wherein one portion comprises a haemopoietin domain or a functional derivative thereof and said other portion comprises an immunoglobulin (Ig)-like domain or a functional derivative thereof whereas said polypeptide exhibits cytokine, such as LIF binding properties. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3823983-A4 |
| priorityDate |
1997-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |